Multimodal assessment of mitochondrial function in Parkinson's disease
Brain · 04.01.2024 · 147 (1) · 267-280
DOI: 10.1093/brain/awad364 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 07.12.2023. Verfasst von Thomas Payne und 14 weiteren Autor:innen. Beteiligte Einrichtung: Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield S10 2HQ, UK. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Michael J Fox Foundation, National Institute of Health Research, Sheffield Biomedical Research Centre.
Abstract (Originalsprache)
The heterogenous aetiology of Parkinson's disease is increasingly recognized; both mitochondrial and lysosomal dysfunction have been implicated. Powerful, clinically applicable tools are required to enable mechanistic stratification for future precision medicine approaches. The aim of this study was to characterize bioenergetic dysfunction in Parkinson's disease by applying a multimodal approach, combining standardized clinical assessment with midbrain and putaminal 31-phosphorus magnetic resonance spectroscopy (31P-MRS) and deep phenotyping of mitochondrial and lysosomal function in peripheral tissue in patients with recent-onset Parkinson's disease and control subjects. Sixty participants (35 patients with Parkinson's disease and 25 healthy controls) underwent 31P-MRS for quantification of energy-rich metabolites [ATP, inorganic phosphate (Pi) and phosphocreatine] in putamen and midbrain. In parallel, skin biopsies were obtained from all research participants to establish fibroblast cell lines for subsequent quantification of total intracellular ATP and mitochondrial membrane potential (MMP) as well as mitochondrial and lysosomal morphology, using high content live cell imaging. Lower MMP correlated with higher intracellular ATP (r = −0.55, P = 0.0016), higher mitochondrial counts (r = −0.72, P < 0.0001) and higher lysosomal counts (r = −0.62, P = 0.0002) in Parkinson's disease patient-derived fibroblasts only, consistent with impaired mitophagy and mitochondrial uncoupling. 31P-MRS-derived posterior putaminal Pi/ATP ratio variance was considerably greater in Parkinson's disease than in healthy controls (F-tests, P = 0.0036). Furthermore, elevated 31P-MRS-derived putaminal, but not midbrain Pi/ATP ratios (indicative of impaired oxidative phosphorylation) correlated with both greater mitochondrial (r = 0.37, P = 0.0319) and lysosomal counts (r = 0.48, P = 0.0044) as well as lower MMP in both short (r = −0.52, P = 0.0016) and long (r = −0.47, P = 0.0052) mitochondria in Parkinson's disease. Higher 31P-MRS midbrain phosphocreatine correlated with greater risk of rapid disease progression (r = 0.47, P = 0.0384). Our data suggest that impaired oxidative phosphorylation in the striatal dopaminergic nerve terminals exceeds mitochondrial dysfunction in the midbrain of patients with early Parkinson's disease. Our data further support the hypothesis of a prominent link between impaired mitophagy and impaired striatal energy homeostasis as a key event in early Parkinson's disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield S10 2HQ, UK.
- Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, The University of Birmingham, Birmingham B15 2TT, UK.
- The Bioinformatics Core, Sheffield Institute of Translational Neuroscience, University of Sheffield, Sheffield S10 2HQ, UK.
- Molecular Genetics Section, Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD 20814, USA.
- Neurodegenerative Diseases Research Unit, Laboratory of Neurogenetics, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20814, USA.
- Department of Neurology, Johns Hopkins University Medical Center, Baltimore, MD 21287, USA.
ORCID-Profile: Thomas Payne, Sonja Scholz, Oliver Bandmann
Förderung
- Michael J Fox Foundation
- National Institute of Health Research
- Sheffield Biomedical Research Centre
- NIHR Sheffield Clinical Research Facility
Zitieren
APA
Payne, T., Burgess, T., Bradley, S., Roscoe, S., Sassani, M., Dunning, M. J., Hernandez, D., Scholz, S., McNeill, A., Taylor, R., Su, L., Wilkinson, I., Jenkins, T., Mortiboys, H., & Bandmann, O. (2024). Multimodal assessment of mitochondrial function in Parkinson's disease. Brain, 147(1), 267-280. https://doi.org/10.1093/brain/awad364
Vancouver
Payne T, Burgess T, Bradley S, Roscoe S, Sassani M, Dunning MJ, et al. Multimodal assessment of mitochondrial function in Parkinson's disease. Brain. 2024;147(1):267-280. doi:10.1093/brain/awad364
BibTeX
@article{Payne2024,
author = {Payne, Thomas and Burgess, Toby and Bradley, Stephen and Roscoe, Sarah and Sassani, Matilde and Dunning, Mark J and Hernandez, Dena and Scholz, Sonja and McNeill, Alisdair and Taylor, Rosie and Su, Li and Wilkinson, Iain and Jenkins, Thomas and Mortiboys, Heather and Bandmann, Oliver},
title = {Multimodal assessment of mitochondrial function in Parkinson's disease},
journal = {Brain},
year = {2024},
volume = {147},
number = {1},
pages = {267--280},
doi = {10.1093/brain/awad364}
}
EUVIMED